Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

CTI meets officials of FDA's OND to support pixantrone NDA

Cell Therapeutics, Inc. today announced that it has met with officials of the FDA's Office of New Drugs in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application 22-481 support the conclusion that pixantrone is effective for its planned use.

3 Mar 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Threshold Pharmaceuticals, Inc. today announced that the Company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.

17 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system.

6 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

16 Dec 2010

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine and the University of Granada found that cFLIP -an inhibitor of death ligand-induced apoptosis- is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Doxorubicin News and Research

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

CTI meets officials of FDA's OND to support pixantrone NDA

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Breakthrough in cancer research can help reduce heart failure, increase survival rates

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Merck reports GAAP net income of $861 million for 2010

Losartan improves effectiveness of nanotherapeutics against cancer

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Syndax reports promising results from entinostat preclinical studies in breast cancer

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News